Pain Management Drugs Market 2014 - 2018 Global Report

Dallas, TX -- (SBWire) -- 03/31/2014 --Sandlerresearch.org offer Global Pain Management Drugs Market 2014-2018 new research report in its store. R&D activities are increasing due to the strong need for new efficacious and better-tolerated medications. Developing better pain treatments is the main goal of all pain research being conducted by various institutes. Morphine is one such drug that works through the body's natural pain-killing machinery, preventing pain messages from reaching the brain. Patients receiving morphine also face the problem of morphine tolerance. Scientists are working toward the development of a morphine-like drug that will have the pain-deadening qualities of morphine but without the drug's negative side effects, such as sedation and the potential for addiction.

According to the report, one of the main drivers in this market is the increase in global aging population. The rise in aging population has consequently led to an increase in the incidence of diseases such as chronic arthritis, diabetic neuropathy, osteoarthritis, and cancer.

The Global Pain Management Drugs Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Pain Management Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Further, the report states that one of the main challenges is the increase in generic competition. The patent expiry of a drug results in the loss of the exclusive market for that drug, leading to a rapid decline in sales.

The report recognizes the following companies as the key players in Global Pain Management Drugs Market: Abbott Laboratories, Eli Lilly and Co., Endo Health Solutions Inc., Pfizer Inc., Purdue Pharma L.P., Actavis plc, Allergen Inc., Astra Zenca plc, Baxter International Inc., Bayer Healthcare AG, Boehringer Ingelheim GmbH, Boston Scientific Corp., Bristol Myers Squibb Co., Durect Corp., F. Hoffmann La Roche Ltd., Forest Laboratories Inc., GlaxoSmithKline plc, Hospira Inc., Johnson & Johnson, Merck & Co. Inc., Novartis AG, Pain Therapeutics Inc., Sanofi S.A., St. Jude Medical Inc., UCB S.A., Valeant Pharmaceuticals International Inc., and Zalicus Inc.

Buy a copy of report directly @ http://www.sandlerresearch.org/purchase?rname=15959.

Key questions answered in this report:
- What will the market size be in 2018 and what will be the growth rate?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of each of these key vendors?

Media Relations Contact

Sandler Research
http://www.sandlerresearch.org/global-pain-management-drugs-market-2014-2018.html

View this press release online at: http://rwire.com/485091